Crystal Pharmatech Recognized as "Best Partner" by Allorion Therapeutics for Excellent Services

Suzhou, China - Crystal Pharmatech , a leading pharmaceutical services provider, has received recognition from its esteemed partner, Allorion Therapeutics (Boston, USA / Guangzhou, China), an innovative biotech company focused on developing novel drug molecules for oncology and autoimmune diseases. The recognition is in appreciation of Crystal Pharmatech's exceptional services in support of a First-in-Human (FIH) study. This acknowledgement underscores Crystal Pharmatech's remarkable technical performance and diligent efforts in polymorph screening, preformulation, and formulation development to support new chemical entities (NCEs).

In a momentous event held in May 2023, Dr. Zhen Liu , Head of CMC at Allorion Therapeutics, presented the prestigious "Best Partner" commemorative awards to Crystal Pharmatech’s CRO and CDMO business units (known as Crystal Pharmatech and Crystal Formulation Services, CFS, respectively). This remarkable honor reflects years of relentless pursuit in technical and service excellence, serving as a testament to the seamless integration between the two business units.

With a proactive approach to the Allorion Therapeutics partnership, Crystal Pharmatech has adeptly managed projects to ensure timely progress and high-quality results. Both the CRO and CDMO business units have truly stood out, showing remarkable technical achievements throughout various collaborative endeavors:

• Selected the most developable crystalline forms for candidate compounds through swift and systematic polymorph studies.
• Conducted efficient physicochemical property research and evaluation of preclinical formulations.
• Resolved drug crystallization process challenges, achieving ICH-compliant reduction in residual solvent levels.
• Ensured API stability in drug product through innovative formulation and analytical approaches.
• Achieved successful prototype formulation development, overcoming limited API quantities (less than 50g).
• Seamlessly scaled-up and tech transferred the formulation process to another CMO through compaction simulation technology.

During the celebratory ceremony, Dr. Liu and the Allorion Therapeutics delegates visited Crystal Pharmatech's state-of-the-art CFS R&D and GMP facilities in Suzhou, expressing high praise for the advanced formulation development facilities, GMP suites, warehouse, QC laboratory, and engineering facilities.

Dr. Liu expressed his gratitude for Crystal Pharmatech’s technical and service excellence, emphasizing the close partnership and the significant support received:

“The project received FDA approval for clinical trials on May 26. The unwavering support of the Crystal Pharmatech project team is one of the key reasons behind this accomplishment. We look forward to continuing our close partnership in areas such as crystalline form research, formulation development, and production. Together, we will innovate to benefit patients."

Dr. Decheng Ma , CEO of Crystal Formulation Services (CFS), expressed his appreciation for being recognized by Allorion Therapeutics, CFS’s first strategic partner:

“We are extremely honored to receive Allorion’s recognition and be bestowed with the title of 'Best Partner'. This award acknowledges the quality of our formulation CDMO services and inspires us to continue achieving world-renowned development. We remain committed to scientific excellence and quality, continuously refining our systems to better serve domestic and global pharmaceutical companies."

Dr. 敏华陈 , CEO of Crystal Pharmatech, reaffirmed the multinational company's commitment to delivering the best technical solutions to their partners:

"As a cutting-edge precision medicine drug development company, Allorion Therapeutics boasts an internationally renowned leadership team and operates at the forefront of global innovation. We are thrilled to be their strategic partner, providing professional crystalline form and formulation technology services to expedite their drug development endeavors.”

For more information, please visit www.CrystalPharmatech.com, or contact us via [email protected].